newsfilter
← Latest News
Business Wire·

Veradermics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

MANE
  • Veradermics reported positive topline results from Phase 3 Study '304' & 12-month data from Phase 2/3 Study '302' for VDPHL01 in male pattern hair loss.
  • VDPHL01 demonstrated robust hair growth with no treatment-related serious adverse events or cardiac safety signals in male trials.
  • Positive open-label Phase 2 Study '207' results showed rapid hair growth in women, marking the first positive Phase 2 trial for an oral female pattern hair loss treatment in the U.S.
  • Enrollment is complete for registration-directed Phase 2/3 Study '306' evaluating VDPHL01 in women, with topline data expected in the first half of 2027.
  • Cash, cash equivalents, & marketable securities totaled $798.4 million as of September 30, 2026, funding operations through 2030.
  • Research & development expenses were $16.1 million for the quarter ended September 30, 2026, down from $18.1 million in the prior year.
  • General & administrative expenses rose to $12.7 million due to increased personnel costs, stock-based compensation, & commercial readiness fees.
  • Net loss for the third quarter of 2026 was $21.0 million compared to $20.1 million in the same period last year.
  • VDPHL01 is an extended-release oral minoxidil tablet potentially becoming the first FDA-approved oral non-hormonal treatment for pattern hair loss in nearly 30 years.
  • The company holds patent protection for VDPHL01 with the earliest expiring term in 2043.